- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05365620
In-line Mechanical Insufflation-Exsufflation in the Management of Ventilated Patients
In-line Mechanical Insufflation-Exsufflation as an Alternative to Invasive Suction for Secretion Management in Ventilated Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial. The study was carried out in two Intensive Care Units - the Cardiac Surgery ICU at Anzhen Hospital, and the Critical Care Medicine ICU at Tian Tan Hospital - both in Beijing, China, over a 36 month period between July 2015 and July 2018. The study group included patients aged 18 to 75 years undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure.
Subjects were randomized to either a control group, managed for 8 hours with CS whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's, or a study group, managed for 8 hours with automatic IL-MIE treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with CS performed only if signs of airway secretion accumulation manifested despite ongoing IL-MIE. IL-MIE was performed using standard IL-MIE parameters (exsufflation pressure = -60 cm H2O, with flutter, 10 coughs/treatment).
Before each CS treatment, 100% oxygen was administered for one minute, regardless of the patient's baseline oxygen requirement, as per standard operating protocol in that ICU. Before IL-MIE treatments, no additional oxygen was administered beyond the patient's baseline oxygen requirement.
Pharmacological management in both groups included analgesia and sedation as routinely used postoperatively in those ICU's.
Demographic information and vital signs were recorded for all subjects. Arterial partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2 ) and oxygenation index (PaO2/FiO2) were defined as the primary end points of the study, and arterial partial pressure of carbon dioxide (PaCO2), pulseoximetry (SpO2), heart rate (HR), and ventilator parameters (inspired oxygen, tidal volume [Vt], peak inspiratory pressure [PIP], airway plateau pressure [Pplat], and PEEP) as secondary end points.
All primary and secondary end-point data were recorded at baseline (2 minutes prior to starting the trial), and at 5 minutes, 4 hours and 8 hours after commencement of the trial. The number of CS treatments performed on each subject was recorded throughout the trial. Follow up for adverse events was performed during, and 48 hours after completion of, the trial.
Statistical Analysis:
The minimum sample size required to demonstrate non-inferiority, was calculated to be 49 in each cohort, or a total of 98 subjects in total.
Collected data were analyzed with a mixed model with repeated measures (MMRM) considering all observations (2 minutes before commencement of the trial protocol, and at 5 minutes, 4 hours and 8 hours thereafter) and accounting for the baseline value of oxygenation. For the indices of oxygenation derived from blood gas measurements (PaO2, SaO2 , and oxygenation index), non-inferiority was evaluated by comparison to the two-sided 95% confidence interval of the treatment effect in the MMRM model, with non-inferiority between the IL-MIE and control cohorts established if the lower limit of the 95% confidence interval for the intergroup difference in least squares mean for a measured index was found to be higher than the pre-determined non-inferiority margin for that index. For comparison of other quantitative data between groups, a two-sample t-test or Wilcoxon rank sum test was used, based on the data distribution. For between-group comparison of subjects with significant adverse events, a chi-square test was used. The number of CS treatments performed in each cohort was analyzed post-hoc as an exploratory analysis.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients undergoing mechanical ventilation during the immediate recovery period following a cardiac or neuro-surgical procedure
- Ventilation expected to last more than 8 hours
Exclusion Criteria:
- acute spinal cord shock
- recent airway trauma or surgery
- cardiogenic pulmonary edema or ARDS necessitating ventilation with a peak end expiratory pressure (PEEP) equal to or greater than 6 cmH2O
- pneumothorax
- hemoptysis
- severe ischemic heart disease
- lung tumors
- pulmonary Tuberculosis
- history of lung transplantation
- pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Catheter Suction
Patients in this arm were managed for 8 hours with Catheter Suction whenever the subject showed signs of airway secretion accumulation, as per standard clinical practice for those ICU's
|
catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
|
|
Experimental: Mechanical Inexsufflation
Patients in this are were managed for 8 hours with automatic inexsufflation treatments (CoughSync, Ruxin Medical Systems Company Ltd, Beijing, China) performed automatically every 30 minutes, and with Catheter Suction performed only if signs of airway secretion accumulation manifested
|
In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use .
IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations.
Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation.
Figure 1 demonstrates the setup and mode of operation of an IL-MIE device.
The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PaO2
Time Frame: change from baseline to 5 minutes
|
Arterial partial pressure of oxygen
|
change from baseline to 5 minutes
|
|
PaO2
Time Frame: change from baseline to 4 hours
|
Arterial partial pressure of oxygen
|
change from baseline to 4 hours
|
|
PaO2
Time Frame: change from baseline to 8 hours
|
Arterial partial pressure of oxygen
|
change from baseline to 8 hours
|
|
SaO2
Time Frame: change from baseline to 5 minutes
|
arterial oxygen saturation
|
change from baseline to 5 minutes
|
|
SaO2
Time Frame: change from baseline to 4 hours
|
arterial oxygen saturation
|
change from baseline to 4 hours
|
|
SaO2
Time Frame: change from baseline to 8 hours
|
arterial oxygen saturation
|
change from baseline to 8 hours
|
|
PaO2/FiO2
Time Frame: change from baseline to 5 minutes
|
oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen
|
change from baseline to 5 minutes
|
|
PaO2/FiO2
Time Frame: change from baseline to 4 hours
|
oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen
|
change from baseline to 4 hours
|
|
PaO2/FiO2
Time Frame: change from baseline to 8 hours
|
oxygenation index - the ratio of blood oxygen to the percentage of inspired oxygen
|
change from baseline to 8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PaCO2
Time Frame: change from baseline to 5 minutes
|
arterial partial pressure of carbon dioxide
|
change from baseline to 5 minutes
|
|
PaCO2
Time Frame: change from baseline to 4 hours
|
arterial partial pressure of carbon dioxide
|
change from baseline to 4 hours
|
|
PaCO2
Time Frame: change from baseline to 8 hours
|
arterial partial pressure of carbon dioxide
|
change from baseline to 8 hours
|
|
SpO2
Time Frame: change from baseline to 5 minutes
|
blood oxygen saturation
|
change from baseline to 5 minutes
|
|
SpO2
Time Frame: change from baseline to 4 hours
|
blood oxygen saturation
|
change from baseline to 4 hours
|
|
SpO2
Time Frame: change from baseline to 8 hours
|
blood oxygen saturation
|
change from baseline to 8 hours
|
|
heart rate
Time Frame: change from baseline to 5 minutes
|
heart rate
|
change from baseline to 5 minutes
|
|
heart rate
Time Frame: change from baseline to 4 hours
|
heart rate
|
change from baseline to 4 hours
|
|
heart rate
Time Frame: change from baseline to 8 hours
|
heart rate
|
change from baseline to 8 hours
|
|
inspired oxygen
Time Frame: change from baseline to 5 minutes
|
percent fraction inspired oxygen
|
change from baseline to 5 minutes
|
|
inspired oxygen
Time Frame: change from baseline to 4 hours
|
percent fraction inspired oxygen
|
change from baseline to 4 hours
|
|
inspired oxygen
Time Frame: change from baseline to 8 hours
|
percent fraction inspired oxygen
|
change from baseline to 8 hours
|
|
ventilator tidal volume
Time Frame: change from baseline to 5 minutes
|
tidal volume in ml
|
change from baseline to 5 minutes
|
|
ventilator tidal volume
Time Frame: change from baseline to 4 hours
|
tidal volume in ml
|
change from baseline to 4 hours
|
|
ventilator tidal volume
Time Frame: change from baseline to 8 hours
|
tidal volume in ml
|
change from baseline to 8 hours
|
|
ventilator peak inspiratory pressure
Time Frame: change from baseline to 5 minutes
|
peak airway pressure in CMH2O
|
change from baseline to 5 minutes
|
|
ventilator peak inspiratory pressure
Time Frame: change from baseline to 4 hours
|
peak airway pressure in CMH2O
|
change from baseline to 4 hours
|
|
ventilator peak inspiratory pressure
Time Frame: change from baseline to 8 hours
|
peak airway pressure in CMH2O
|
change from baseline to 8 hours
|
|
ventilator peak airway plateau pressure
Time Frame: change from baseline to 5 minutes
|
airway plateau pressure in CMH2O
|
change from baseline to 5 minutes
|
|
ventilator peak airway plateau pressure
Time Frame: change from baseline to 4 hours
|
airway plateau pressure in CMH2O
|
change from baseline to 4 hours
|
|
ventilator peak airway plateau pressure
Time Frame: change from baseline to 8 hours
|
airway plateau pressure in CMH2O
|
change from baseline to 8 hours
|
|
ventilator peak end expiratory pressure
Time Frame: change from baseline to 5 minutes
|
airway end expiratory pressure in CMH2O
|
change from baseline to 5 minutes
|
|
ventilator peak end expiratory pressure
Time Frame: change from baseline to 4 hours
|
airway end expiratory pressure in CMH2O
|
change from baseline to 4 hours
|
|
ventilator peak end expiratory pressure
Time Frame: change from baseline to 8 hours
|
airway end expiratory pressure in CMH2O
|
change from baseline to 8 hours
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 047-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.